Efficacy and Tolerability of Low-Dose Thalidomide as First-Line Systemic Treatment of Patients with Advanced Hepatocellular Carcinoma

Publisher： Karger

E-ISSN： 1423-0232|72|1|67-71

ISSN： 0030-2414

Source： Oncology, Vol.72, Iss.1, 2007-12, pp. : 67-71

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Low-Dose Thalidomide Treatment for Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 65, Iss. 3, 2003-12 ,pp. : 242-249

Karger

Access to resources Recommend Favorite

Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer

By  

Oncology, Vol. 87, Iss. 2, 2014-07 ,pp. : 104-113

Karger

Access to resources Recommend Favorite

Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study

By  

Oncology, Vol. 85, Iss. 1, 2013-07 ,pp. : 44-52

Karger

Access to resources Recommend Favorite

The Safety and Efficacy of Low‐dose Tissue Plasminogen Activator in the Treatment of Systemic Sclerosis

By  

THE JOURNAL OF DERMATOLOGY, Vol. 22, Iss. 9, 1995-09 ,pp. : 637-642

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 82, Iss. 2, 2012-02 ,pp. : 119-125

Karger

Access to resources Recommend Favorite